Study record · Sobetirome
Historical sobetirome Phase I single- and multiple-dose study (reported in peer-reviewed reviews)
Peer-reviewed reviews report LDL-C reductions up to 22% after single-dose exposure and up to 41% after the two-week multiple-dose phase.
Key result
Peer-reviewed reviews report LDL-C reductions up to 22% after single-dose exposure and up to 41% after the two-week multiple-dose phase.
Study details
Study designRandomized, double-blind, placebo-controlled early clinical study as reported in reviews
PhasePhase I
PopulationAdult participants
Sample size32 single-dose; 24 multiple-dose
RouteOral
Regimen / exposureSingle ascending doses; repeated dosing for two weeks
DurationUp to 2 weeks
ComparatorPlacebo
Primary endpoint / questionLipid lowering and short-term tolerability
Safety resultReviews report no obvious extrahepatic effects during the short exposure.
Key limitationsPrimary full clinical report was not located; the result is described in later peer-reviewed reviews and historical meeting reporting. Long-term outcomes are unknown.
Registry / identifierHistorical Phase I; secondary peer-reviewed source